The BioHub - by Avetix

Today I’m joined by Rich Daly, CEO of Catalyst Pharmaceuticals — one of the standout rare-disease success stories in the industry and recently named one of America’s most successful small-cap companies by Forbes.Rich has spent more than 25 years leading organisations across biotech and pharma — including AstraZeneca, BeyondSpring, CARsgen, and others — and now he’s steering Catalyst as they expand their portfolio, grow their footprint, and continue delivering life-changing treatments for patients with rare neuromuscular and neurological diseases.We talk about what drew him to Catalyst, how the company thinks about growth, patient service, and rare-disease strategy, how they find the right drugs in a competitive market, and how Catalyst continues to outperform despite the volatility across biotech.Let’s get into it.

Jason Ehrlich, physician-scientist and CEO of Ollin Biosciences, blends clinical insight with biotech leadership. He discusses building a pipeline for serious eye diseases, designing optimized bispecific therapies like OLIN-324 and OLN-102, strategies for efficient clinical development and fundraising, and creating a remote, science-first company culture.

In this episode of The BioHub, I’m joined by Dr. Adam Mendelsohn, Co-Founder and CEO of Vivani Medical.Adam’s journey spans bioengineering at UCSF and UC Berkeley to founding Nano Precision Medical and now leading Vivani following its 2022 merger. Vivani is developing long-term, sub-dermal drug implants designed to transform treatment for chronic diseases such as obesity and diabetes.We discuss the science behind the platform, why long-acting implants could shift the treatment paradigm, what’s happening at Vivani right now, and what it takes to build and finance a biotech company in today’s market.

🎙 New Episode Live – Todd Zavodnick, CEO of ExcellergyTodd Zavodnick is the CEO of Excellergy, a clinical-stage biotechnology company redefining allergy treatment. Their mission? To make therapies faster, more effective, and far more convenient for patients — transforming the experience of managing allergies.Before Excellergy, Todd built a track record of leadership in biotech, bringing together scientific rigor and strategic vision to tackle complex challenges in patient care.In this episode, we discuss:Excellergy’s approach to improving existing allergy therapies and what sets them apart in the field.Clinical milestones, including their Phase 1 launch in Australia and plans for Phase 2 next year.The patient impact — how Excellergy is aiming to reduce wait times and make treatment truly transformative.Whether you’re interested in biotech innovation, clinical development, or patient-centric therapies, this conversation is packed with insight.

Today’s guest is Terry J. Rosen, a scientist-entrepreneur who has helped shape the modern era of cancer immunotherapy.Dr. Rosen is the co-founder and CEO of Arcus Biosciences, a clinical-stage biotechnology company focused on developing innovative immuno-oncology therapies and combination treatments designed to transform outcomes for patients with cancer. Before launching Arcus, he co-founded Flexus Biosciences, which was acquired by Bristol-Myers Squibb in 2015—an early validation of his vision in immune-based therapies.Across his career, Terry has held senior scientific and leadership roles at major biopharmaceutical organizations including Amgen, Pfizer, and Abbott Laboratories, building a track record that bridges rigorous medicinal chemistry with bold company creation.In this we discuss:Arcus' pipeline and what makes them stand out from other companies in the immuno-oncology fieldWhat makes Arcus a compelling investment opportunity today and how they balance the long timelines and risks of drug development with the expectations of public markets and investors?The key milestones for Arcus in the next year to18 months that the scientific and investment communities should be paying attention to

In this episode of The BioHub, I’m joined by Thijs Spoor, CEO of Perspective Therapeutics.Thijs has taken an unconventional path to the CEO seat, bringing decades of leadership experience across healthcare and capital markets into one of the most exciting areas of biotech: targeted radiopharmaceuticals.We talk about his journey into the industry, the science and vision behind Perspective, the company’s recent $175M raise, and the milestones that could define their next phase of growth. A great conversation about bold strategy, differentiated science, and building momentum in today’s market.

Prior to JPM 2026 and the news of their recent CSL collaboration, I spoke to Memo Therapeutics' CEO, Erik van den Berg for an episode of The BioHub Podcast.Memo are preparing for a global ph3 trial of Potravitug, their antibody against BK polyomavirus infection in kidney transplant recipients. BKPyV infection can lead to nephropathy, loss of kidney function, as well as organ failure, rejection & death, with the virus residing in up to 90% of the total population.Erik joins us to walk through Memo's late-stage plans, as well as their DROPZYLLA platform, and their early stage oncology programs. He also shares his insight from a varied journey through biotech leadership, including two current Chair roles with former BioHub guests - TargED & Step Pharma.

We were delighted to welcome Declan Doogan, CEO of Causeway Therapeutics, onto The BioHub! Declan is a highly respected leader in the biopharmaceutical industry, with decades of experience spanning drug development, clinical research, and executive leadership at some of the world’s leading pharmaceutical companies.Throughout his career, he has played a pivotal role in advancing innovative therapies from early discovery through to global commercialization. At Causeway Therapeutics, he is leading the charge in developing breakthrough treatments aimed at addressing serious and underserved medical needs.In this we discuss:Entrepreneurship and building a biotech having spent decades in PharmaCauseway's recent encouraging clinic results and what makes there approach different to what's out there alreadyHow Causeway are thinking about the pipeline and upcoming milestones

In this episode of The BioHub, I’m joined by Raj Devraj, CEO of Rectify Pharma and Venture Partner at Atlas Venture.Raj has spent his career building biotech companies around bold science, including co-founding Disarm Therapeutics, which was acquired by Eli Lilly. Now he’s doing it again with Rectify.We talk about starting companies from zero, building the right teams early, de-risking new ventures, and the realities of fundraising in today’s biotech market. A practical, honest conversation with a true biotech builder.

We were delighted to Welcome Jim Jenson, CEO of Morphoecueticals a TechBio company focused on understanding and manipulating the bioelectrome to induce regeneration and treat disease.